Search Result

Results for "

narcolepsy

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (4) Calcium Channel (4) Caspase (4) Cholinesterase (ChE) (1) Dopamine Receptor (1) Dopamine Transporter (1) Drug Derivative (1) Drug Metabolite (1) ERK (2) iGluR (1) Isotope-Labeled Compounds (1) MCHR1 (GPR24) (1) Orexin Receptor (OX Receptor) (18) Phosphodiesterase (PDE) (2) Phospholipase (1) Reference Standards (2) Sigma Receptor (1)
By Research Areas:	Cancer (5) Endocrinology (4) Metabolic Disease (1) Neurological Disease (23)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10805

Almorexant Maximum Cited Publications 9 Publications Verification ACT 078573	Orexin Receptor (OX Receptor) Calcium Channel Caspase Apoptosis	Neurological Disease Endocrinology Cancer
Almorexant (ACT 078573) is an orally active, potent and competitive dual orexin receptor antagonist, with K_d values of 1.3 nM (OX1) and 0.17 nM (OX2), respectively. Almorexant reversibly blocks signaling of orexin-A and orexin-B peptides. Almorexant totally blocked the intracellular Ca ²⁺ signal pathway. Almorexant stimulates caspase-3 activity in AsPC-1 cells and induces apoptosis .

HY-159835

Oveporexton TAK-861	Orexin Receptor (OX Receptor)	Neurological Disease
Oveporexton (TAK-861) is an orally active and selective orexin receptor 2 (OX2R) agonist with an EC₅₀ of 2.5 nM. Oveporexton exhibits 3000-fold selectivity for OX2R over OX1R. Oveporexton can be used for the study of hypersomnia disorders including narcolepsy .

HY-133898

Danavorexton TAK-925	Orexin Receptor (OX Receptor)	Others
Danavorexton (TAK-925) is an orexin receptor agonist with brain permeability. Danavorexton induces a physiological pattern of OX2R activation in vitro to wake up sleepy mice and improve sleepiness symptoms .

HY-172412

Alixorexton ALKS 2680	Orexin Receptor (OX Receptor)	Neurological Disease
Alixorexton (ALKS 2680) is an orally bioavailable, blood-brain barrier-permeable OX2R-selective activator and wake-promoting agent. Alixorexton can be used for the research of narcolepsy and idiopathic hypersomnia .

HY-10805A

Almorexant hydrochloride Maximum Cited Publications 9 Publications Verification ACT 078573 hydrochloride	Orexin Receptor (OX Receptor) Calcium Channel Caspase Apoptosis	Neurological Disease Endocrinology Cancer
Almorexant (ACT 078573) hydrochloride is an orally active, potent and competitive dual orexin receptor antagonist, with K_d values of 1.3 nM (OX1) and 0.17 nM (OX2), respectively. Almorexant hydrochloride reversibly blocks signaling of orexin-A and orexin-B peptides. Almorexant hydrochloride totally blocked the intracellular Ca ²⁺ signal pathway. Almorexant hydrochloride stimulates caspase-3 activity in AsPC-1 cells and induces apoptosis .

HY-111178

Lauflumide BisfluoroModafinil; CRL-40940	Drug Derivative	Neurological Disease
Lauflumide (BisfluoroModafinil) is the common alternative of modafinil. Modafinil is commonly prescribed for the research narcolepsy. Lauflumide has the potential for cognitive enhancing .

HY-136181A

YNT-185 1 Publications Verification	Orexin Receptor (OX Receptor)	Neurological Disease
YNT-185 is a nonpeptide, selective orexin type-2 receptor (OX2R) agonist, with EC₅₀s of 0.028 and 2.75 μM for OX2R and OX1R, respectively. YNT-185 ameliorates narcolepsy-cataplexy symptoms in mouse models .

HY-W042214

Ritalinic acid Ritalinate	Drug Metabolite	Others
Ritalinic acid (Ritalinate) is the main inactive urinary metabolite of Methylphenidate. Methylphenidate has the potential for attention-deficit hyperactivity disorder and narcolepsy research .

HY-137440A

Firazorexton hydrate TAK-994	Orexin Receptor (OX Receptor) ERK	Neurological Disease
Firazorexton hydrate (TAK-994) is an orally active and brain-penetrant orexin type 2 receptor (OX2R) selective agonist. Firazorexton hydrate can promote wakefulness and has the potential to improve narcolepsy-like symptoms in mice .

HY-136181

YNT-185 dihydrochloride	Orexin Receptor (OX Receptor)	Neurological Disease
YNT-185 dihydrochloride is a nonpeptide, selective orexin type-2 receptor (OX2R) agonist, with EC₅₀s of 0.028 and 2.75 μM for OX2R and OX1R, respectively. YNT-185 dihydrochloride ameliorates narcolepsy-cataplexy symptoms in mouse models .

HY-137440

Firazorexton TAK-994 free base	Orexin Receptor (OX Receptor) ERK	Neurological Disease
Firazorexton (TAK-994 free base) is an orally active and brain-penetrant orexin type 2 receptor (OX2R) selective agonist. Firazorexton (TAK-994 free base) can promote wakefulness and has the potential to improve narcolepsy-like symptoms in mice .

HY-P1341

OXA(17-33) Orexin A (17-33) (human, mouse, rat, bovine)	Orexin Receptor (OX Receptor) Sigma Receptor Phospholipase	Neurological Disease
OXA (17-33) (Orexin A (17-33) (human, mouse, rat, bovine)) is the shortest active orexin peptide that selectively targets OX1 (EC₅₀=8.29 nM), with 23-fold selectivity for the OX1 receptor over the OX2 receptor. The activity of OXA (17-33) depends on the Tyr17, Leu20, Asn25, His26 residues and the spatial conformation of the α-helix. OXA (17-33) activates signaling pathways involving inositol-1,4,5-trisphosphate receptor (IP3R), phospholipase D (PL-D) and choline-Sigma-1R, thereby increasing the cytoplasmic Ca ²⁺ level in nucleus accumbens neurons, an effect that is blocked by Sigma-1R antagonists. OXA (17-33) serves as an important biological probe for investigating the function of the OX1 receptor. OXA (17-33) can be modified via incorporation of mixed disulfide bonds of homocysteine and cysteamine, and is widely used in studies related to insomnia and narcolepsy .

HY-177073

Cleminorexton	Orexin Receptor (OX Receptor)	Neurological Disease Metabolic Disease
Cleminorexton is an orally active orexin-2 receptor (OX2R) agonist with a pEC₅₀ between 9 and 10.4. Cleminorexton can be used for narcolepsy and other conditions associated with orexin deficiency and/or excessive sleepiness .

HY-101490

PDE1-IN-2	Phosphodiesterase (PDE)	Neurological Disease
PDE1-IN-2 is a PDE1 inhibitor extracted from patent WO2016/55618 A1, example 31. PDE1-IN-2 has IC₅₀ values of 6 nM, 140 nM and 164 nM for PDE1C, PDE1B and PDE1A, respectvely. PDE1-IN-2 is developed for the research of neurodegenerative disorders and psychiatric disorders .

HY-W039283

MCH-1 antagonist 2	MCHR1 (GPR24)	Neurological Disease Cancer
MCH-1 antagonist 2 (l-BROMO-2,4-DIFLUORO-5-NITROBEN-ZENE) is a melanin concentrating hormone-1 (MCH1) receptor-selective 4-aryl piperidine. MCH-1 antagonist 2 can be used for the research of depression, anxiety, obesity, urge incontinence, urinary incontinence, major depression, bipolar disorder, agoraphobia, specific phobia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, acute stress disorder, urinary frequency, urinary urgency, nocturia, enuresis, bulimia, bulimia nervosa, anorexia nervosa, major depressive disorder, dysthymic disorder, bipolar 1 and 2 disorders, schizoaffective disorder, cognitive disorders with depressed mood, personality disorders, insomnia, hypersomnia, narcolepsy, circadian rhythm sleep disorder, nightmare disorder, sleep terror disorder, sleepwalking disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, overactive bladder .

HY-172672

Orexin 2 Receptor Agonist 3	Orexin Receptor (OX Receptor)	Neurological Disease
Orexin 2 Receptor Agonist 3 (Compound 57) is an orally active and brain-penetrant orexin receptor type-2 (OX₂) agonist (EC₅₀: 2.5 nM). Orexin 2 Receptor Agonist 3 increases wakefulness in the orexin/ataxin-3 NT1 mouse model and healthy beagle dogs. Orexin 2 Receptor Agonist 3 can be used in the study of narcolepsy .

HY-137440B

(2R,3R)-Firazorexton (2R,3R)-TAK-994 free base	Orexin Receptor (OX Receptor)	Neurological Disease
(2R,3R)-Firazorexton ((2R,3R)-TAK-994 free base) is an isomer of Firazorexton (HY-137440). Firazorexton is an orally active, brain-penetrating orexin type 2 receptor (OX2R) agonist that may improve narcolepsy-like symptoms ..

HY-159731

OX2R agonist 1	Orexin Receptor (OX Receptor)	Neurological Disease
OX2R agonist 1 is an OX2R antagonist with an EC₅₀ of less than 100 nM. OX2R agonist 1 can be used in research related to excessive daytime sleepiness or narcolepsy .

HY-B0949S

Protriptyline (N-methyl-d3) hydrochloride	Isotope-Labeled Compounds Cholinesterase (ChE)	Neurological Disease
Protriptyline (N-methyl-d₃) (hydrochloride) is the deuterium labeled Protriptyline hydrochloride. Protriptyline hydrochloride is a tricyclic antidepressant (TCA), specifically a secondary amine, for the treatment of depression and ADHD. Unique among the TCAs, protriptyline tends to be energizing instead of sedating, used for narcolepsy to achieve a wakefulness-promoting effect .

HY-161567

OX2R-IN-3	Orexin Receptor (OX Receptor)	Neurological Disease
OX2R-IN-3 (Compound 53) is an orally active type 2 orexin receptor (OX2R) agonist (EC₅₀<100 nM.) .

HY-163276

OX2R agonist 3	Orexin Receptor (OX Receptor)	Neurological Disease
OX2R agonist 3 (compound 63c) is an agonist for orexin receptor type 2 (OX2R) with EC₅₀ of 339 nM. OX2R agonist 3 is able to cross the blood-brain barrier and exhibits no cytotoxicity in cells

HY-10805R

Almorexant (Standard) ACT 078573 (Standard)	Orexin Receptor (OX Receptor) Calcium Channel Caspase Apoptosis Reference Standards	Neurological Disease Endocrinology Cancer
Almorexant (Standard) is the analytical standard of Almorexant. This product is intended for research and analytical applications. Almorexant (ACT 078573) is an orally active, potent and competitive dual orexin receptor antagonist, with Kd values of 1.3 nM (OX1) and 0.17 nM (OX2), respectively. Almorexant reversibly blocks signaling of orexin-A and orexin-B peptides. Almorexant totally blocked the intracellular Ca2+ signal pathway. Almorexant stimulates caspase-3 activity in AsPC-1 cells and induces apoptosis .

HY-183324

AMPA receptor modulator-12	iGluR Dopamine Transporter	Neurological Disease
AMPA receptor modulator-12 is an orally acrive AMPA receptor positive allosteric modulator. AMPA receptor modulator-12 also exhibits moderate binding affinity for the human dopamine transporter with a K_d of 1.57 μM. AMPA receptor modulator-12 enhances AMPA receptor-mediated ion currents, delays channel deactivation. AMPA receptor modulator-12 prolongs sleep latency, reduces sleep duration, extends forced swimming time, improves rotarod endurance, and alleviates acute sleep deprivation-related behavioral deficits. AMPA receptor modulator-12 does not increase spontaneous locomotion. AMPA receptor modulator-12 can be used for the research of narcolepsy and fatigue-related conditions .

HY-182327

PDE1-IN-12	Phosphodiesterase (PDE) Dopamine Receptor	Neurological Disease
PDE1-IN-12 (P78, the first compound in 12) is a PDE1 inhibitor. PDE1-IN-12 inhibits PDEl-mediated suppression of the dopamine D1 receptor intracellular pathway and can be used for narcolepsy .

HY-10805AR

Almorexant hydrochloride (Standard) ACT 078573 hydrochloride (Standard)	Reference Standards Orexin Receptor (OX Receptor) Calcium Channel Caspase Apoptosis	Neurological Disease Endocrinology Cancer
Almorexant hydrochloride (Standard) is the analytical standard of Almorexant (hydrochloride) (HY-10805A). This product is intended for research and analytical applications. Almorexant (ACT 078573) hydrochloride is an orally active, potent and competitive dual orexin receptor antagonist, with K_d values of 1.3 nM (OX1) and 0.17 nM (OX2), respectively. Almorexant hydrochloride reversibly blocks signaling of orexin-A and orexin-B peptides. Almorexant hydrochloride totally blocked the intracellular Ca2+ signal pathway. Almorexant hydrochloride stimulates caspase-3 activity in AsPC-1 cells and induces apoptosis .

Cat. No.	Product Name	Target	Research Area

HY-P1341

OXA(17-33) Orexin A (17-33) (human, mouse, rat, bovine)	Orexin Receptor (OX Receptor) Sigma Receptor Phospholipase	Neurological Disease
OXA (17-33) (Orexin A (17-33) (human, mouse, rat, bovine)) is the shortest active orexin peptide that selectively targets OX1 (EC₅₀=8.29 nM), with 23-fold selectivity for the OX1 receptor over the OX2 receptor. The activity of OXA (17-33) depends on the Tyr17, Leu20, Asn25, His26 residues and the spatial conformation of the α-helix. OXA (17-33) activates signaling pathways involving inositol-1,4,5-trisphosphate receptor (IP3R), phospholipase D (PL-D) and choline-Sigma-1R, thereby increasing the cytoplasmic Ca ²⁺ level in nucleus accumbens neurons, an effect that is blocked by Sigma-1R antagonists. OXA (17-33) serves as an important biological probe for investigating the function of the OX1 receptor. OXA (17-33) can be modified via incorporation of mixed disulfide bonds of homocysteine and cysteamine, and is widely used in studies related to insomnia and narcolepsy .

Cat. No.	Product Name	Chemical Structure

HY-B0949S

Protriptyline (N-methyl-d3) hydrochloride
Protriptyline (N-methyl-d₃) (hydrochloride) is the deuterium labeled Protriptyline hydrochloride. Protriptyline hydrochloride is a tricyclic antidepressant (TCA), specifically a secondary amine, for the treatment of depression and ADHD. Unique among the TCAs, protriptyline tends to be energizing instead of sedating, used for narcolepsy to achieve a wakefulness-promoting effect .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.